Key Takeaways
- Export pivot drives 16% growth: Revenue rose 16.1% YoY as exports surged to 68% of the mix from 49% a quarter ago, offsetting a domestic dip.
- Margins are healing, not healed: Gross margin improved QoQ to ~45% but remains below the 50%+ peak because high-cost raw material inventory is still working through the system.
- New products are the FY24 story: Seven of eight IPO-promised molecules are now launched, and management expects them to contribute ~₹250 Cr of incremental revenue next year.
- Hamirpur greenfield is the medium-term unlock: Environmental clearance is in hand, first units should start by December, and the company plans ~₹100 Cr of annual capex there for the next four years.
- What to watch next quarter: Whether gross margin recovers as high-cost inventory is consumed, the pace of new herbicide offtake in Q4 and Q1, and any update on the eighth molecule launch.
Export Surge & Demand Drivers
- Export mix flipped: Exports jumped to ₹148 Cr from ₹109 Cr YoY while domestic fell to ₹69 Cr from ₹81 Cr, shifting the export share to 68% from 49% in Q2. Strong herbicide demand and new molecule launches drove the move.
- Herbicide tailwind: A recently commissioned herbicide plant (~300 tonnes capacity) is seeing very good export demand, with major sales expected in Q4-end and Q1 when seasonal usage peaks.
- Europe pull: Good demand is coming from Europe and adjoining countries for one herbicide launched last year.
- Domestic softness is seasonal, not structural: Q3 is a lean season domestically; major consumption happens in Q2, so Q1 and Q2 sales run higher and Q3 flattens. The company was building local inventory for late-Q3 and Q4 sales.
- Volume and price both contributed: Q3 saw 8% volume growth and 8% price growth YoY, splitting the 16% revenue increase evenly.
- Competitive moat vs China: Major competitors for top products are based in Israel, not Europe, and Chinese manufacturers of these compounds are relatively very small, so competitive pressure from China is limited.
D K Jain: "from China we have not so much of competition at all because the manufacturers of these compounds in China are relatively very small."
Margin Dynamics & Cost Pressures
- Gross margin improved but not recovered: Gross margin rose QoQ from ~43% to ~45%, but remains below the 50% mark achieved in earlier quarters because high-cost raw material inventory imported earlier to avoid stock-out risk has not yet been fully consumed.
- High-cost inventory drag: The company imported significant inventory in the initial period to prevent production disruption and is still carrying those stocks. Management expects to utilize this high-cost inventory by Q4 FY2023, which should improve margins next quarter.
- Energy cost bite: Rice husk prices surged from ~₹300/quintal to ₹1,100 and now range ₹850–900, adding meaningful pressure to the manufacturing cost structure. The company uses rice husk, not coal, for steam and hot water generation.
- Cost pass-through is partial: Raw material cost increases are passed on to customers per contractual arrangements, but overall manufacturing cost and energy cost become difficult to pass on, creating a residual margin effect.
- Inventory level normalization is structural, not temporary: Inventory closed at ₹225 Cr in December, flat with September. Management expects a ₹25 Cr reduction by year-end, but inventory will not return to earlier levels because new products have seasonal Kharif demand requiring anticipatory build-up.
D K Jain: "Sir actually the ultimate usage price in the market that does not get absorbed probably that is why we are not able to pass on the complete cost increase, though we have an arrangements with the companies and the raw material cost we are able to pass on but the overall manufacturing cost and the energy cost that becomes difficult for us to pass on that is why there is some effect on us."
D K Jain: "50- 51% it will be very difficult to say but we will try our maximum whatever is possible."
New Product Engine & Capacity Build
- Seven of eight IPO molecules launched: Six active ingredients and one intermediate are now commercialized; the intermediate is largely an import substitute aligned with Atmanirbhar Bharat. The eighth molecule is already under construction and planned for launch soon.
- New product contribution scaling: Newly launched products contributed ₹25 Cr in Q3 FY2023 versus ₹12–13 Cr in Q3 FY2022. The seven launched molecules are expected to generate ₹250 Cr of revenue in FY2024.
- Four more launches planned for FY24: At least two products in the subsidiary and two in the existing plant. Existing site capex will also yield two more products, taking the total from the existing site to nine instead of the original eight.
- Sandila brownfield nearly full: The current ₹70 Cr capex (₹54 Cr spent in 9M, balance by March) will fill the Sandila site almost completely, leaving very small space for one or two small products. Further expansion will largely come from the new Hamirpur site.
- Asset turnover expectation: The ₹140 Cr of cumulative brownfield capex (₹70 Cr earlier plus ₹70 Cr current) is expected to contribute ~2.5x asset turnover. Full utilization of expanded capacity is targeted by end of FY2024.
- Utilization snapshot: Technicals utilization was ~72% in 9M FY2023; formulations utilization was only ~40% due to channel inventory in local markets and the off-season.
D K Jain: "Our strategy is that way only Sir that we would like to be backward integrated company. We do very few products N minus one strategy."
Hamirpur Greenfield: The Next Leg
- Environmental clearance secured: The Ministry of Environment and Forests granted clearance for the Hamirpur project under wholly owned subsidiary Shalvis Specialties, covering technicals capacity of 36,000 tonnes per annum and formulations capacity of 29,200 tonnes per annum.
- Other clearances progressing: Ground water abstraction clearance received, fire NOC received, and an agreement with Ramky for landfill systems is in place.
- Timeline: First two units expected operational by December/January. Contribution from the site will be nominal in FY2024 because plants will be under stabilization; meaningful contribution begins from FY2025 onwards.
- Capex plan: ~₹10 Cr spent to date, another ₹7–10 Cr in the next two months. Planned capex for next year at the new site is ~₹100 Cr, with a projection of ~₹100 Cr per annum for the coming four years as the company builds capacity in blocks.
- Chemistry expansion: The greenfield will target new molecules and new chemistries involving bromine, fluorine, and other process chemistries beyond the current portfolio.
- Customer pipeline building: Discussions are ongoing with US, Australian, and Japanese companies for new products. Registration studies including five-batch reports, physical-chemical properties, and toxicological studies are underway for submissions in various countries.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| High-cost inventory consumption | Utilize high-cost raw material inventory, improving margins | Q4 FY2023 |
| Sandila capex completion | Balance of ₹70 Cr FY2023 capex completed | Before March 2023 |
| FY2024 topline | "Easily" reach ~₹1,000–1,100 Cr with existing plants | FY2024 |
| New product revenue contribution | ~₹250 Cr incremental turnover from new capacities | FY2024 |
| New product gross margins | ~46–47% (down from earlier 50%+ yardstick due to inflation) | FY2024 |
| Capacity utilization | Full utilization of expanded Sandila capacity | End of FY2024 |
| Hamirpur first units operational | First two units start production | December/January 2023–24 |
| Hamirpur meaningful contribution | Site contributes materially after stabilization | FY2025 onwards |
| New product launches | At least four products: two in subsidiary, two in existing plant | FY2024 |
| Eighth molecule launch | Already under construction, launch planned soon | Undated |
| EBITDA margin | 23% to 25% projected | FY2024 |
| Inventory reduction | Reduce by at least ₹25 Cr from December level | By year-end FY2023 |
| Hamirpur annual capex run-rate | ~₹100 Cr per annum | Coming four years |
S P Gupta: "EBITDA margin we are projecting next year is between 23 to 25% and since our product has very stable pricing environment the presence of China is very less so we do not see much downward risk due to price reduction but even our buyers they are not able to increase price very much so stable kind of environment we are projecting as far as pricing is concerned."
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Total revenue | ₹222 cr, +16% YoY |
| EBITDA | ₹51 cr, margin of ~22% |
| PAT | ₹35 cr, vs ₹43 cr in Q3 FY22; PAT margin 15.7% |
| Export revenue | ₹148 cr, vs ₹109 cr in Q3 FY22 |
| Domestic revenue | ₹69 cr, vs ₹81 cr in Q3 FY22 |
| Technicals revenue | ₹184 cr |
| Formulations revenue | ₹34 cr |
| Export share of revenue | 68%, up from 49% in Q2 FY23 |
| Volume growth (YoY) | +8%, price also +8%, total revenue growth 16% |
| Technicals volume sold | >4,000 tonnes, vs ~3,900 tonnes in Q2 FY23 |
| Gross margin | ~45%, improved from ~43% QoQ; high-cost inventory still being consumed |
| New product contribution (quarter) | ~₹25 cr, vs ~₹12–13 cr in Q3 FY22 |
| New product contribution (9M FY23) | ~12% of sales |
| Technicals utilization (9M FY23) | ~72% |
| Formulations utilization (9M FY23) | ~40%, impacted by channel inventory and off-season |
| Inventory closing value | ~₹225 cr, flat vs Q2 FY23; expected to reduce by at least ₹25 cr by year-end |
| FY24 EBITDA margin guidance | 23–25% |
| FY24 incremental revenue from new capacities | ~₹250 cr expected |
| Hamirpur capex spent till date | ~₹10 cr, further ₹7–10 cr expected in next two months |
| Sandila capex done in 9M FY23 | ₹54 cr of the planned ₹70 cr for FY23 |